Imvax Appoints John P. Furey as Chief Executive Officer
September 10, 2019 07:00 ET
|
Imvax, Inc.
PHILADELPHIA, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Imvax, Inc., a discovery and clinical-stage biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy...
Imvax Announces Positive Results from Clinical Trial of Novel IGV-001 Autologous Cell Vaccine in Treating Patients with Newly Diagnosed Glioblastoma
March 31, 2019 15:00 ET
|
Imvax, Inc.
Median overall survival was 21.9 months for highest vaccine dose vs. 14.6 months in published standard of care studies Median progression-free survival was 10.4 months vs. 6.9 and 5.4 months in...
Imvax to Present Results from Phase 1b Clinical Trial of IGV-001 in Glioblastoma Multiforme at the American Association for Cancer Research Annual Meeting 2019
March 27, 2019 08:00 ET
|
Imvax, Inc.
PHILADELPHIA, March 27, 2019 (GLOBE NEWSWIRE) -- Imvax, Inc., a clinical-stage biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies,...